P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Myeloma Patient-Derived Mesenchymal Stem Cells Grown In 3-D Culture Induce Primary Myeloma Cell Proliferation and Resistance To Therapy
Jana Jakubikova,Richard W.J. Groen,Teru Hideshima,Danka Cholujova,Jan Sedlak,Constantine S. Mitsiades,Jacob P. Laubach,Nikhil C. Munshi,Paul G. Richardson,Kenneth C. Anderson +9 more
TL;DR: To define the functional myeloma niche, key hematopoietic and/or neoplastic niche molecules were investigated by analyzing 30 MM-MSCs and 5 healthy volunteers MSCs as well as cancer biomarkes performed by multiplex luminex technology.
Journal ArticleDOI
Commentary: monitoring for myelosuppression in IBD – authors’ reply
Jason K. Hou,Jason K. Hou,Jennifer R. Kramer,Jennifer R. Kramer,Paul G. Richardson,Paul G. Richardson,Shubhada Sansgiry,Shubhada Sansgiry,Hashem B. El-Serag,Hashem B. El-Serag +9 more
TL;DR: The timing of myelosuppression during thiopurine therapy for inflammatory bowel disease: implications for monitoring recommendations are discussed.
Journal ArticleDOI
The BAFF Inhibitor AMG523 Blocks Adhesion and Survival of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment: Clinical Implication.
Yu-Tzu Tai,Jiangchun Xu,Xian-Feng Li,Iris Breitkreutz,Klaus Podar,Teru Hideshima,Robert L. Schlossman,Paul G. Richardson,Nikhil C. Munshi,Kenneth C. Anderson +9 more
TL;DR: The data demonstrate that the novel therapeutic AMG523 blocks the interaction between BAFF and its receptors in human MM, thereby providing the rationale for clinical trials of AMG522 to improve patient outcome in MM.
Journal ArticleDOI
Final Results of a Phase 1/2 Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of Evofosfamide, a Hypoxia-Activated Prodrug, and Dexamethasone with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma
Jacob P. Laubach,Noopur Raje,Andrew Yee,Philippe Armand,Robert L. Schlossman,Jacalyn Rosenblatt,Michael Gary Martin,Craig W. Reynolds,Kenneth H. Shain,Ira Zackon,Laura Stampleman,Emily Lai,Aaron M. Caola,Joseph Cappuccio,Bradley Rivotto,Kaitlen Reyes,Alexandra Savell,Patrick Henrick,Tillman E. Pearce,Damian Handisides,Stew Kroll,Kenneth C. Anderson,Paul G. Richardson,Irene M. Ghobrial +23 more
TL;DR: This phase 1/2 study was conducted to determine the maximum tolerated dose (MTD), safety, tolerability, and clinical activity of the hypoxia-activated prodrug evofosfamide and dexamethasone with or without bortezomib in relapsed/refractory multiple myeloma.
Journal ArticleDOI
Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
Ajay K. Nooka,Jonathan L. Kaufman,Cesar Rodriguez,Andrzej Jakubowiak,Yvonne A. Efebera,Brandi Reeves,Tanya M. Wildes,Sarah A. Holstein,Larry D. Anderson,Ashraf Badros,Leyla Shune,Ajai Chari,Huiling Pei,Annelore Cortoos,Sharmila Patel,J. Blake Bartlett,Jessica Vermeulen,Thomas S. Lin,Paul G. Richardson,Peter M. Voorhees +19 more